NJ Innovation Evergreen Fund Invests $4.65M in 5 Startups

The New Jersey Economic Development Authority has closed on $4.65 million in investments for five New Jersey companies through the New Jersey Innovation Evergreen Fund, the agency announced this month.

The five companies, spread across Mercer, Camden and Hudson counties, received the funding through qualified venture firms that applied on their behalf. The businesses are Antigenix Therapeutics in Princeton, PolyGone Systems in Kearny, TranscendAP in Hamilton, Lula Inc. in Voorhees and Synchrony Medical in Jersey City.

The Evergreen Fund works differently from a typical grant program. Under its structure, the state takes an equity stake in early-stage companies alongside private venture capital firms, rather than simply writing checks with no expectation of return. The program can deploy up to $600 million total, making it one of the larger public venture commitments in the state’s history.

NJEDA CEO Evan S. Weiss said the fund reflects the administration’s focus on building out New Jersey’s startup economy. “The New Jersey Innovation Evergreen Fund is a cutting-edge initiative designed to strengthen the state’s economy by leveraging both public and private capital to support high-growth startups and entrepreneurs,” Weiss said in a statement. “Governor Sherrill and the NJEDA have been laser-focused on bolstering the innovation economy, creating jobs and supporting the next generation of transformative companies.”

The fund currently has about $78 million in unallocated capital available for additional investments. The NJEDA also recently completed an $85 million tax credit auction to raise more money, with proceeds expected to become available for investment in early 2026. Combined, that gives the fund roughly $60 million in capital ready to deploy into new deals right now.

The mechanism behind the fundraising is worth understanding. The NJEDA auctions tax credits to corporations and investors. Those buyers don’t just get the tax benefit; they also commit to providing strategic support to New Jersey’s startup ecosystem. That can include financial contributions to university programs, support for nonprofits and Strategic Innovation Centers, mentoring and other educational programming. Those commitments factor into how bids are scored, so the auction process is designed to pull in partners who will do more than write a check.

The 29 venture capital firms currently approved to work within the fund span a range of investment strategies, industries and company stages. That diversity matters because early-stage companies in pharma, medtech, logistics software and other sectors don’t all need the same kind of backing.

For New Jersey, the geography of these five investments tells a story about where the state is trying to build momentum. Princeton has long anchored biotech and pharmaceutical research in the state. Kearny and Jersey City sit within the broader Hudson County corridor that connects New Jersey to New York’s financial networks. Hamilton and Voorhees represent the state’s effort to extend innovation activity beyond its most established hubs.

New Jersey has historically struggled to keep its homegrown startups from migrating to New York or Boston once they reach the stage where serious venture money comes into play. The Evergreen Fund is designed to address that problem by making state capital available in tandem with private investors, reducing the incentive for companies to relocate in exchange for funding.

The stakes are real for workers. Early-stage companies don’t employ thousands of people today, but the ones that succeed tend to build out significant operations over five to ten years. Pharma and medtech startups in particular, if they clear clinical and regulatory hurdles, can become major employers in the state. New Jersey already has a deep workforce in life sciences; keeping young companies here increases the chance that those workers stay employed close to home.

The NJEDA continues to accept applications from venture firms looking to qualify for the program and from approved firms seeking to fund specific companies. Given the $85 million raised in the recent tax credit auction, the fund has room to move quickly on additional deals.